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TObjectives: Autologous skeletal myoblast cell transplantation by means of the
injection method is subject to the loss of intercellular communication, extracellular
matrix, and cell numbers. We hypothesize that the implantation of skeletal myoblast
cell sheets might be more advantageous in repairing the impaired heart by providing
uniform and stable cell delivery with less cell loss and without disrupting the
cell-cell microenvironment.
Methods: Left anterior descending coronary artery–ligated Lewis rat hearts (2
weeks, total n  173) received 1  107 autologous skeletal myoblasts by means of
cell transplantation either through myoblast injection or implantation of 2 monolayer-
constructed myoblast sheets (5  106 cells per sheet) or through medium injection.
Myoblast sheets were constructed with temperature-responsive, polymer-grafted
cell-culture dishes, which release the confluent cells from the dish surface at less
than 20°C.
Results: Echocardiographic results indicated higher improvement of cardiac perfor-
mance in the myoblast sheet group than among the other groups until 8 weeks after
cell transplantation. Histologic comparison revealed greater cellularity and abundant
widespread neocapillaries within the noticeable uniform thickened wall in myoblast
sheet group hearts only. Fibrosis was substantially reduced with skeletal myoblast
sheet implantation compared with skeletal myoblast cell injection. Obviously higher
numbers of hematopoietic stem cells (c-kit, stem cell antigen 1, and CD34) were
observed in the myoblast sheet group infarct heart region. Reverse transcription–
polymerase chain reaction results showed expression of stromal-derived factor 1,
hepatocyte growth factor, and vascular endothelial growth factor as follows: myo-
blast sheets  myoblast injection  control.
Conclusions: Myoblast sheets repaired the impaired myocardium, reduced fibrosis,
and prevented remodeling in association with recruitment of hematopoietic stem
cells through the release of stromal-derived factor 1 and other growth factors. Our
experiment indicates a therapy for patients with severe heart failure.
Devastating myocardial infarction leads to heart failure if left untreated andunsupported. After damage, the heart is capable of a very limited regener-ative capacity.1,2 Heart transplantations and mechanical support with left
ventricular (LV) assist systems are supportive in patients with heart failure but are
subject to a few important limitations, such as organ rejection, donor shortage,
infections, and durability of the assist systems. Autologous cellular cardiomyoplasty
(cell transplantation [Ctx]) overcomes these shortcomings and has emerged as an
independent potential therapy to regenerate-repair lost myocardium and improve
cardiac function.3
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CSPSkeletal myoblasts maintain muscle regenerative quality
with growing power to millions and act as the most suitable
autologous cell type for clinical application.4 Several labo-
ratories have reported improved heart performance with
myoblast transplantation.5-7 However, the use of trypsin to
detach the cells from the culture dish disrupts their micro-
intercellular communication and extracellular matrix, re-
stricts cell survival and growth, and thus appears deleterious
to Ctx therapy.8 Intercellular communication factors play a
key role in cell adhesion, migration, proliferation, differen-
tiation, and death9 and must be maintained for optimal
cellular benefits. We believe that the selection of a reliable
cell delivery mode that maintains the potentiality of the cells
is as valuable as the type and the number of cells.
Tissue engineering for tissue regeneration fulfills the
criteria to repair the heart and eliminates several draw-
backs.10 The use of scaffold for tissue engineering is sup-
portive for myocardial regeneration but subject to biocom-
patibility, biodegradability, and cytotoxicity, including
inflammatory response and surface adhesion molecule loss
issues, and this limits its efficacy. Eliminating such disad-
vantages, we have established cell sheet engineering tech-
nology without using scaffolds.11 The engineered cell sheets
from this technique showed preserved cellular communica-
Abbreviations and Acronyms
ANOVA  analysis of variance
BrdU  5=-bromo-2=-deoxyuridine
Ctx  cell transplantation
EF  ejection fraction
HGF  hepatocyte growth factor
HSC  hematopoietic stem cell
LAD  left anterior descending coronary artery
LV  left ventricular
MHC myosin heavy chain
MI group myoblast cell suspension injection
MS group myoblast cell sheet implantation
RT-PCR  reverse transcription–polymerase chain
reaction
Sca-1  stem cell antigen 1
SDF-1  stromal-derived factor 1
VEGF  vascular endothelial growth factor
TABLE 1. Distribution of animals
Groups
Cell therapy
animals (total)
Echocardiography at 2,
4, and 8 weeks
MS 29  1† n  5
MI 25  5† n  5
C 29  1† n  5
Total 173 Lewis rats. RT-PCR, Real-time reverse transcription–polymeras
MI, myoblast injection; C, medium injection. *Histologic staining (hematoxylin a
1334 The Journal of Thoracic and Cardiovascular Surgery ● Novtion junctions, endogenous extracellular matrix, and inte-
grative adhesive agents.12 Nonligature implantation of our
engineered neonatal cardiomyocyte sheets to infarcted myo-
cardium showed their integration with impaired myocar-
dium and improved cardiac performance.13 For clinical ap-
plication, use of skeletal myoblasts averts ethical and cell
source issues. Thus we selected autologous skeletal myo-
blasts and constructed myoblast sheets.
Recent findings suggested that locally or transgenically
delivered stromal-derived factor 1 (SDF-1) expression plays
a role in mobilizing and recruiting stem cells with neovas-
cularization.14 Because SDF-1 is secreted in skeletal muscle
tissue,15 grafted myoblasts might beneficially attract hema-
topoietic stem cells (HSCs) to home in the infarct heart area
for heart regeneration and angiogenesis.
We proceeded to investigate whether the myoblast sheets
serve as a suitable and potential cell carrier and cell deliverer
for heart repair, attract hematopoietic stem cells–progenitor
cells by releasing SDF-1, and tame cardiac remodeling to
improve deteriorated heart geometry and function.
Materials and Methods
Animals
One hundred seventy-three female and male Wistar-Lewis rats
(180-220 g, 6-10 weeks old; Seac Yoshitomi Ltd) were used for
myoblast donors and recipients for this study. Humane animal care
was used in compliance with the “Principles of Laboratory Animal
Care” formulated by the National Society for Medical Research
and the “Guide for the Care and Use of Laboratory Animals”
prepared by the Institute of Animal Resources and published by
the National Institutes of Health (National Institutes of Health
publication no. 86-23, revised 1985). Distribution of 173 rats is
shown in Table 1.
Isolation of Myoblasts and Construction of Myoblast
Sheets
Isolation and expansion of myoblasts was performed (n  40 rats
in the myoblast cell suspension injection [MI] group and n  43
rats in the myoblast cell sheet implantation [MS] group and each
Ctx group) with a modified protocol, as previously described.16
Cells were delivered to the infarcted hearts either by means of
direct intramyocardial injection or implantation of constructed
myoblast sheets.
Custom-made culture dishes coated with thermoresponsive
polymers and poly-N-isopropylacrylamide were used to construct
taining at
14 d*
RT-PCR at 7 d/DB at 7
and 14 d
Animal no.:
myoblast isolation
n 10 n  14 n 43
n 10 n  10 n 40
n 9 n  15 n 0
in reaction; DB, double immunofluorescence staining; MS, myoblast sheet;S
e cha
nd eosin, Masson trichrome, factor VIII). †Mortality number.
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Pthe myoblast sheets, as previously described.17 The surfaces of
these dishes are hydrophobic at 37°C and become hydrophilic at
temperatures of less than 20°C. The cell suspensions with a density
of 5 106 were plated in the thermoresponsive cell-culture dish at
37°C in an incubator for 1 to 2 days. The confluent cells cultured
on these dishes at 37°C are spontaneously detached by placing
them at 20°C for 1 hour. Free monolayer cell sheets are thus
attained in the manner. The size of these cell sheets ranged to 1.00
0.05 cm2 in area and 50  10.0 m in thickness (Figure 1, B and
C). Finally, 2 sheets were piled to make a thicker sheet for grafting.
Thus one graft for implantation contained around 1.0  107 cells.
Cell count from a single myoblast sheet showed recovery of 5 
106  5693.96 cells.
Surgical Procedure
The anesthetized rats (ketamine and xylazine) were intubated, and
positive-pressure ventilation was maintained with a ventilator
(model SN-480-7 Shinano). Thoracotomy was performed between
the fourth and fifth intercostal spaces, and acute myocardial in-
farction was induced in the rats by means of ligation of the left
anterior descending coronary artery (LAD), as previously de-
scribed.18 After 2 weeks, depending on the mode of therapy, the
rats were randomly divided into 3 treatment groups: (1) MS group
(n  29, 1  107 cells per sheet); (2) MI group (n  25, 1  107
cells in 0.2 mL of Dulbecco’s modified Eagle’s medium); and (3)
medium injection group (control group, n  29). The cells in the
MI group were transplanted by injecting at 5 sites in and around
the infarcted region with a 30-gauge tuberculin syringe, and the
same number of cells was delivered in the MS group by implanting
the cell sheets directly over the scar area without sutures. After
treatment, a biodegradable collagen sheet (Ø33mm; Kokencellgen)
was overlapped on the hearts to avoid adhesion to the chest wall
(Figure 1, E).
The Journal of ThoracicAssessment of Cardiac Performance
After achievement of anesthesia, heart function was monitored at
baseline (2 weeks after LAD ligation and before Ctx) and at 2, 4,
and 8 weeks after Ctx (n  5 in each group at each time point).
Echocardiography was performed with an ultrasound machine
(SONOS 5500, Agilent Technologies) equipped with an annular
array transducer operating at 12 Mhz. The heart was first imaged
in the 2-dimensional mode in short-axis views at the level of the
largest LV diameter. The systolic and diastolic LV area was
determined at the same time. The calculation of LV volume was
based on the LV short-axis area. This view was used to position the
M-mode cursor perpendicular to the LV anterior and posterior
wall. Diastolic measurements were measured at the time of the
apparent maximal LV diastolic dimension. The LV end-systolic
dimension was measured at the time of the most anterior systolic
excursion of the LV posterior wall. The LV dimension at end
diastole and LV dimension at end systole were determined. Minor
axis anterior-inferior wall dimensions were used. Dimensions and
area data are presented as the average of measurements of 3
selected beats. LV ejection fraction (EF) was calculated by
using the following formula: LVEF %  LVDd3 
LVDs3 ⁄ LVDd3  100. End-diastolic area and end-systolic area
were determined to evaluate the percentage of fractional area
shortening by using the following formula: FAS %  EDA 
ESA ⁄ EDA 100 %.
Histologic Examination
Hematoxylin and eosin and Masson trichrome staining were car-
ried out 2 weeks after the treatments to evaluate the histologic
nature of infarcted lesions in each group. Treated hearts from each
group (MS group, n  10; MI group, n  10; control group, n 
Figure 1. Immunohistochemical staining (A;
40 magnification) showed that roughly 60%
to 70% of cultured cells were desmin-positive
muscle lineage cells. Hematoxylin and eosin
(B) and Masson trichrome staining (C; 400
magnification) indicated high cellularity and
low fibrous content of the myoblast sheet
(scale bar  50 m). Two sheets were piled
to make a composite sheet graft (D). Grafts
implanted to the infarcted area of a rat heart
are shown in E.9) were removed and fixed with 10% formalin. At least 3 step
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CSPsections at the middle portion of the left ventricle were prepared
for each heart, and anterior wall thickness was measured in the
sections.
Paraffin blocks were sectioned, deparaffinized, and immuno-
stained with the following antibodies: monoclonal anti-skeletal
myosin antibody to fast-twitch skeletal myosin heavy chain
(MHC; MY-32, Sigma, St Louis, Mo) and monoclonal anti-myosin
(skeletal, slow) directed against skeletal slow MHC isoforms
(NOQ7.5.4D, Sigma).
Immunohistochemical staining for von Willebrand factor anti-
gen was performed with DAKO’s EPOS von Willebrand factor/
horseradish peroxidase kit (DakoCytomation, Denmark) to detect
vessels in the infarcted area, according to the manufacturer’s
protocol. Ten low-power fields per section were analyzed to assess
the vascular density at 100 magnification. The results were
expressed as the number of blood vessels per square millimeter.
The percentage of the total fibrotic area was quantified by
means of image analysis of the Masson trichrome–stained sections
by means of the planimetric method with MetaMorph software
(UIC). Ten low-power fields per section were analyzed to assess
the fibrous contents in the infarcted area (Olympus, Japan).
Characterization of Dividing Cells on the Basis of
5=-Bromo-2=-Deoxyuridine Administration
5=-Bromo-2=-deoxyuridine (BrdU), 50 mg · kg1 · d1, was intra-
peritoneally injected into the treated rats for 5 consecutive days
beginning from the day of myoblast implantation, as previously
described, to identify and characterize dividing cells in infarcted
areas of the treated hearts.14 The numbers of animals for each
treatment group in this set of experiments was 14 for the MS
group, 10 for the MI group, and 15 for the control group. The
hearts were removed 7 or 14 days after the implantation of myo-
blasts and cut into 2 pieces. One set of pieces was frozen in liquid
nitrogen and sectioned for immunohistochemical staining. The
other half was stored in RNAlater solution (QIAGEN) for subse-
quent RNA extraction.
The anti-BrdU In-Situ Detection Kit (BD Pharmagen) was used to
observe the BrdU-positive cells in the infarcted heart, according to the
manufacturer’s protocol. The sections of experimental cardiac muscle
tissue were immunostained with antibodies against CD34, c-kit
(CD117), von Willebrand factor (all from Santa Cruz, Inc), stem
cell antigen 1 (Sca-1; BD Inc), and Troponin-T (NeoMarkers). For
immunostaining, tissue was fixed for 10 minutes with 4% para-
formaldehyde. After the primary antibody incubation, the follow-
ing secondary antibodies (all material from Molecular Probes, Inc)
were used: goat anti-mouse Alexa Flour 488, goat anti-mouse
Alexa Flour 546, goat anti-rabbit Alexa Flour 546, and donkey
anti-goat Alexa Flour 546. After the double primary antibody
staining, BrdU staining was performed (anti-bromodeoxyuridine,
mouse IgG1, monoclonal PRB-1, Alexa Fluor 488 conjugate).
Cover slips were finally mounted with SlowFade Antifade kit
reagents with 4,6-diamino-2-phenylindole nuclear dye. Slides
were viewed with a fluorescent microscope equipped with differ-
ential interference contrast optics (Polaroid, Olympus, Japan). The
number of stained cells per square millimeter at 10 different fields
(100) was counted.
1336 The Journal of Thoracic and Cardiovascular Surgery ● NovQuantitation of Gene Transcripts by Means of
Real-Time Reverse Transcription–Polymerase Chain
Reaction
Total RNA was isolated from the stored specimen with RNeasy
Mini Kit (QIAGEN) and reverse transcribed with Omniscript
Reverse Transcriptase (QIAGEN). Real-time reverse transcrip-
tion–polymerase chain reaction (RT-PCR) was performed with
ABI PRISM 7700, as previously described.19,20 The sequence of
forward primers, reverse primers, and probes for SDF-1 and re-
duced glyceraldehyde-phosphate dehydrogenase is not shown. The
measurement for each gene, each RNA sample, was performed in
triplicate. RT-PCR was performed to measure the expression of
SDF-1, hepatocyte growth factor (HGF), and vascular endothelial
growth factor (VEGF) in only specimens stored for 7 days.
Statistical Analysis
All data are presented as means  standard deviation and sub-
jected to multiple analysis of variance (ANOVA) with StatView
5.0 software (Abacus Concepts). Time-course data shown in Fig-
ure 2 were first analyzed by using repeated-measurements 2-way
ANOVA, and further comparisons for the specific 2 groups were
carried out with the Tukey-Kramer post hoc test. The other nu-
meric data were analyzed by using 1-way ANOVA, and the
significance of the comparisons was tested with the Bonferroni
method.
Results
Effect of Myoblast Transplantation on Cardiac
Performance
Myocardial infarction resulted in less than 20% acute mor-
tality within 24 hours of the operation (not added to total
number of animals). Few animals died at the time of reop-
eration (MS group, n  1; MI group, n  5; and control
group, n  1). Ventricular remodeling after weeks of LAD
ligation characteristically resulted in both global cavity en-
largement and cardiac pump dysfunction, as measured with
echocardiography at baseline. At 2, 4, and 8 weeks, control
group hearts showed deterioration in EF, with dilatation of
the ventricular chamber. The MI group showed improved
EF (2, 4, and 8 weeks) compared with that seen in the
control group but did not show any significant reduction in
LV chamber dilatation compared with the other groups.
However, sheet implants in the MS group resulted in sig-
nificant improvement in EF at 2, 4, and 8 weeks compared
with that seen in the control group and significant improve-
ment in EF at 2 and 4 weeks compared with that seen in the
MI group. The reduction in LV chamber area was evident
after treatment in the MS group only. LV end-systolic area
was significantly reduced in the MS group at 4 and 8 weeks,
whereas LV end-diastolic area was significantly reduced in
the MS group at 4 and 8 weeks. The percentage of fractional
area shortening was significantly improved in the MS group
compared with in the other groups at 2 and 4 weeks (Figure 2).
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PHistologic Findings
Before myoblast implantation, the anterior wall of the left
ventricle was already replaced by fibrous scar, and it was
much thinner compared with other healthy parts of the left
ventricle (Figure 3, baseline). Two weeks after the treat-
ment, the control and MI groups showed similar morphol-
ogy to that observed at baseline, although the MI group
showed isolated cells inside the scar tissues. However, MS
group hearts revealed that the anterior wall was richly
cellularized and mainly occupied by round or oval-shaped
cellular contents, which were uniformly distributed within
the anterior wall, replacing the scar area (Figure 3, A). The
MS group showed a uniform and significantly thicker ante-
rior wall (Figure 3, B). There was no major difference in the
thickness of the anterior walls among the baseline, MI, and
control groups. Significant reduction of myocardial fibrosis
was observed in the anterior wall of the hearts in the MI
group when compared with that seen in the control group.
However, the reduction of fibrosis was much more evident
in the MS group (Figure 3, C) compared with that seen in
the MI and control groups. Histologic observations and
quantifications were mainly conducted 14 days after Ctx.
A cellular layer (partial or complete) of elongated myo-
fibers was observed in the epicardial region in MS group
Figure 2. Improved cardiac performance was observe
represents 2 weeks after the left anterior descending c
(LVESA); B, left ventricular end-diastolic area (LVEDA)
fractional area shortening (FAS). *P < .05 versus cont
injection group. BL, Baseline; MS, myoblast sheet grohearts. In MI group hearts we observed small and isolated
The Journal of Thoracicmyofibers, mainly in the midmyocardial region. After 2
week of Ctx, serial sections immunostained by directing
against the fast MHC isoform indicated the graft occupation
by skeletal muscle structures, mainly fast-twitch fibers. A
small percentage, approximately 20%, stained positive for
slow MHC, showing conversion to slow-twitch myofibers.
In the MI group we observed small and isolated myofibers
surrounded by collagenous contents, mainly in the midmyo-
cardial region.
Local capillary density in the anterior wall was evaluated
in each group. Both the MI and MS groups showed in-
creases in the number of local capillaries. Quantification of
the vascular density at 2 weeks showed obviously higher
numbers of vessels in the MS group (26.1  4.7  102/
mm2, P  .0001) versus the MI group (14.4  3.4 
102/mm2) and versus the control group (4.1  2.1  102/
mm2). The MI group (14.4  3.4  102/mm2) showed
significantly higher vascular density versus the control
group (4.1  2.1  102/mm2, P  .0001).
Immunofluorescence Staining
Double staining count for BrdU and different cells markers
(c-kit, Sca-1, and CD34) at 14 days showed a greater
presence of these cells in MS hearts compared with in MI
myoblast sheet implantation group hearts. Baseline
ary artery ligation. A, left ventricular end-systolic area
eft ventricular ejection fraction (LVEF) ; D, Percentage
roup; #P < .05, myoblast sheet group versus myoblast
I, myoblast injection group; C, control group.d in
oron
; C, l
rol g
up; Mand control hearts (Figure 4, A).
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CD34 cells in the infarct heart zone of animals treated with
myoblast sheets was significantly higher per square milli-
meter compared with that seen in the animals treated with
myoblast injection and the control group (Figure 4, C). At
day 7, the number of these positively stained cells was
slightly higher in all groups compared with on day 14 but
significantly higher in the MS group only (data not shown).
Assessment of Growth Factors by Gene Expression
RT-PCR analysis after 1 week of Ctx showed higher ex-
pression of SDF-1 in the MS group compared with that in
the control groups as follows: MS group (0.09  0.02, P 
.05)  MI group (0.05  0.02)  control group (0.02 
0.01; Figure 4, D). Expression of the genes encoding SDF-1
and HGF was lowest in the infarcted area of control group
hearts, and they tended to increase in those of the MI group
(P  .05). RT-PCR results also showed significantly higher
expression of growth factors (HGF and VEGF) by MS
group hearts after the myoblast sheet implantation com-
pared with after Ctx by means of needle injection in MI
group hearts and control group hearts (Figure 4, E and F),
1338 The Journal of Thoracic and Cardiovascular Surgery ● Novwhereas expression levels of VEGF in the control and MI
groups were similar.
Discussion
In this study we aimed to determine whether engineered
autologous myoblast sheets repair the infarcted myocardial
wall to attenuate cardiac remodeling for improving cardiac
performance.
The concept of regenerative medicine and tissue engi-
neering is to deliver healthy cells to the damaged or dis-
eased tissues of the organ and stimulate their endogenous
system of repair and regeneration for the desired organs.21
Tissue engineering, which is based on scaffold use, rescues
the damaged tissue through tissue regeneration. However,
Zimmermann and colleagues22 and Kofidis and associates23
have reported several potential drawbacks accompanying
scaffold tissue constructs.
Beneficial for Ctx, as reported by Kushida and cowork-
ers,24 the cell sheet tissue maintains intact membrane pro-
teins and adhesive proteins, incorporates extracellular ma-
Figure 3. A, Macroscopic (10) and mi-
croscopic (400) view of hearts from
baseline (BL), control (C), myoblast injec-
tion (MI), and myoblast sheet implantation
(MS) groups are shown. The baseline
hearts that were excised 2 weeks after
left anterior descending coronary artery
ligation showed complete scar formation
in the infarcted area, and the area in the
control group showed similar findings.
Histology was also similar in the MI
group, although we observed dispersed
cellularity in the scar area. The infarcted
areas in the MS group were occupied
with highly cellular tissues. The anterior
wall was significantly thicker in the MS
group only compared with the MI and con-
trol groups (B). The degree of myocardial
fibrosis was similar in the baseline and
control groups, and it was reduced in the
MI group (C). The percentage of fibrosis in
the MS group, however, was markedly
less compared with that in the MI and
control group. *P < .05 versus control
group; #P < .05, MS group versus MI
group.trix molecules, and secretes growth factors caused by
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Pfavorable cell-to-cell cross-talk and prevents cellular micro-
environment disruption caused by enzymatic reactions
(trypsin or dispase) for cell detachment from cell-culture
dishes.
After myoblast sheet implantation, the MS group dem-
onstrated uniform repair in the anterior wall, which proba-
bly played a primary role in reremodeling the geometry of
the LV chamber. The reasoning for this attenuation of
remodeling appears to be the efficient delivery of myoblast
in the form of sheets that overlapped the scar area and its
borders in the form of a cellular bridge. A primary and
well-maintained cellular microenvironment in myoblast
sheets probably supports all necessary cellular activities (eg,
Figure 4. Greater cellularity was observed in the myo
was seen in the myoblast injection (MI) group (A, m
fluorescent images were merged to reveal areas of cos
(400 magnification). BrdU-positive cells were observ
Detection Kit (B). Higher numbers of HSCs were obser
only (C). *P < .05 versus control group; #P < .05, MS
stromal-derived factor 1 (SDF-1; D), hepatocyte growt
(VEGF ; F) genes was measured 1 week after myoblast
the MS group. *P < .05 versus control group; #P < .0release of growth factors). In the case of the MI group,
The Journal of Thoracictransplanted cells settle in the cavities surrounded by the
fibrous scar without any intercellular communication and
begin their basic but delayed establishment of microenvi-
ronment, which proves fatal for their primary survival.
The greater cellularity might be, additionally, a result of
the potential role of released SDF-1 and other growth fac-
tors by transplanted cells, which involves cell migration,
adhesion, and proliferation. We detected the expression of
SDF-1 by the myoblast sheets in vitro (data not shown).
Because HSCs bears CXCR4 receptors and establish a
coupling balance with stem cell homing factor–specific
ligand, SDF-1, and maintain their homing within the bone
marrow, the recruitment of HSCs through SDF-1 release
sheet (MS) group (A, right), whereas less cellularity
) and the control (C) group (A, left). Double-staining
ng, as evidenced by yellowish-orange staining pattern
the infarcted heart region with the anti-BrdU In-Situ
n the infarcted repairing myocardium in the MS group
p versus MI group. Relative levels of expression for
tor (HGF ; E), and vascular endothelial growth factor
lantation and was measured as significantly higher in
group versus MI group.blast
iddle
taini
ed in
ved i
grou
h fac
imp
5 MSfrom myoblast sheets might associate with its mechanism
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CSPfor greater cellularity and repair.14,15 Similarly, the greater
release of HGF and VEGF in MS group hearts compared
with in MI group hearts might also play an advantageous
role for damaged hearts. Myoblasts act as the natural sup-
plier of growth factors, such as HGF, and proved to be an
angiogenic and antifibrotic factor by using it for their own
growth and recruitment of other cells.25
Findings by Balsam and colleagues26 demonstrated the
continuing hematopoietic fate of HSCs in ischemic myocar-
dium. Two weeks after Ctx, we similarly observed abundant
c-kit, Sca-1, and CD34 marker expressing cells. Murry and
associates27 stated the nontransdifferentiation of HSCs into
cardiac myocytes, but the findings by Orlic and coworkers28
showing the extensive conversion of Lin c-kit bone mar-
row cells to myocytes remain controversial. The exact ex-
tent of benefits by HSCs for better cardiac performance
remains skeptical, but we agree with Askari and col-
leagues14 in stating that the provision of increased cellular-
ity and replacement of the scar area by the presence of
HSCs is primarily responsible for reversing the remodeling
by increasing the LV mass and decreasing LV dilatation.
The replacement of fibrosis by greater cellularity might be
the benefit of HSCs.
Recent groups have reported the existence of cardiac
stem cells in the heart for tissue repair, although its poten-
tiality appears limited.29,30 However, several other works
have reported bone marrow as a real origin of these different
immigrant cells.31 These cells might mobilize under the
influence of chemotactic factors and migrate to the tissue
undergoing repair, either from bone marrow or from within
the heart. In our case a few colocalized endothelial and
cardiac-type cells with BrdU-positive cells were also rarely
observed. Further investigations are needed to show the
exact origin of these HSCs and endothelial cells and their
exact transdifferentiation fate.
We have not quantitatively assessed and compared the
size of grafted myoblasts in both groups; however, in an-
other unpublished experimental study, we have assessed the
survival of implanted cells after treatment in the MI or MS
groups by means of RT-PCR. Myoblasts from male rats
were implanted into female recipients, and the hearts were
removed 1 day after Ctx. Genomic DNA was purified from
the whole heart, and the content of male-specific DNA,
which represented the content of implanted cells after treat-
ment, was measured. MS versus MI group results emerged
as follows: 3.71 0.55 (P .05) versus 1.71 0.50 at day
1. From these results, we also deduce better myoblast sur-
vival with sheet implantation. Although this evaluation only
provides a global assessment of cell survival (eg, myoblasts
and fibroblasts), we find it compatible with our other
findings.
Color kinesis echocardiography results from our past
study showed no recovery in regional systolic function after
1340 The Journal of Thoracic and Cardiovascular Surgery ● Novthe fibroblast sheet implantation,13 and Hutcheson and as-
sociates32 also showed failure in improvement of systolic
function by fibroblast transplantation compared with myo-
blast transplantation. Mesh implantation only supports the
preservation of LV geometry but without improvement in
its regional systolic function.33 These findings prevented us
from using fibroblast sheet or mesh as a control group. We
used biodegradable collagen sheets to avoid chest adhesion,
and their ineffectiveness on remodeling of myocardial ge-
ometry is clearly addressed by control group results.
We conclude that tissue cardiomyoplasty is better than
cellular cardiomyoplasty because it repairs the infarcted
myocardial wall and recruits supportive HSCs to attenuate
cardiac remodeling and improve cardiac performance.
We thank Masako Yokoyama for expert assistance with RT-
PCR and Shigeru Miyagawa for echocardiography.
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